ASMB: Cup Handle detected on 24 Aug 2026

ASMB is a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases. A cup-handle pattern has formed with the stock currently at 34.38, trading 13.4% below its 52-week high but up 70% from its 52-week low. The pattern displays a structure score of 12/15, volume score of 12/12, and breakout score of 13/13—solid technical quality with strong relative volume of 1.5x average. Key resistance sits at 28.96; support is critical at 26.18. The overall pattern scores 81/98 with 54.49% win probability. Volume confirmation is evident, providing a reliable technical setup.

In Q2 2026, Assembly reported expansion of ABI-6250 into cholestatic liver diseases with a Phase 2 study expected to start in Q1 2027, and another Phase 2 in chronic HDV targeted by year-end 2026. The company completed a $115 million gross financing and reported $320.4 million in cash at June 30, 2026, with cash runway projected into 2029. Q2 earnings beat consensus by 71.43%, with a loss of $0.20 per share versus expected $0.70. Collaboration revenue from Gilead rose to $13.4 million from $9.6 million year-over-year. The company's strong cash position, improving financials, and active clinical pipeline with upcoming Phase 2 initiation catalysts support the current bullish price momentum.

A successful cup-handle breakout would target 37.64 (conservative measure move), requiring volume to remain elevated above the 227,166-share 20-day average. Invalidation occurs at 26.18—the critical support level. At current RSI of 70, the stock is overbought, suggesting some pullback risk within the handle before breakout confirmation. The 54.49% win probability indicates this is a moderate-confidence setup. Historical cup-handle patterns of this quality typically see 2-4% measured moves above breakout, though biotech volatility (63.77% 20-day) could amplify moves.

RSI at 70 signals overbought conditions, increasing near-term pullback risk. Phase 2 initiation for GS-1179 in recurrent genital herpes is expected by year-end 2026, creating execution risk if timelines slip. Beta of 0.58 provides some downside protection but limits upside in biotech rallies. The stock's 36% gain over one month suggests extended price action—mean reversion or consolidation is possible. Upcoming milestones (Q1 2027 Phase 2 start, year-end HDV Phase 2) are binary events that could trigger sharp reversals. High volatility (5.26% ATR) and biotech sector noise present additional uncertainty.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.